scholarly journals The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation

2001 ◽  
Vol 86 (8) ◽  
pp. 3480-3487 ◽  
Author(s):  
Joan C. Lo ◽  
Kathleen Mulligan ◽  
Mustafa A. Noor ◽  
Jean-Marc Schwarz ◽  
Robert A. Halvorsen ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Composition ◽  
Glucose Metabolism ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Fat Accumulation

scholarly journals Body composition in children receiving recombinant human growth hormone after renal transplantation

1998 ◽  
Vol 54 (3) ◽  
pp. 951-955 ◽  
Author(s):  
Janusz Feber ◽  
Pierre Cochat ◽  
Jan Lebl ◽  
Hana Krásničanová ◽  
Jan Štěpán ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Composition ◽  
Renal Transplantation ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth

scholarly journals Effects of Recombinant Human Growth Hormone on Hepatic Lipid and Carbohydrate Metabolism in HIV-Infected Patients with Fat Accumulation

2002 ◽  
Vol 87 (2) ◽  
pp. 942-945 ◽  
Author(s):  
Jean-Marc Schwarz ◽  
Kathleen Mulligan ◽  
Jeongae Lee ◽  
Joan C. Lo ◽  
Michael Wen ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Lipid Profile ◽  
Human Growth Hormone ◽  
Disease Risk ◽  
Recombinant Human Growth Hormone ◽  
Cardiovascular Disease Risk ◽  
Human Growth ◽  
Metabolic Effects ◽  
Gh Treatment ◽  
Fat Accumulation

We recently reported that treatment with a pharmacologic dose of recombinant human growth hormone (GH) resulted in a significant loss of body fat and gain in lean tissue in HIV-infected patients with syndromes of fat accumulation. However, insulin-mediated glucose disposal decreased transiently after one month of GH therapy. The present paper focuses on the changes of hepatic carbohydrate and fat metabolism associated with GH treatment in the same subjects. We assessed hepatic insulin sensitivity under both fasting and hyperinsulinemic-euglycemic clamp conditions prior to and after one and six months of GH treatment (3 mg/day) in five patients using stable isotope tracer techniques. Indirect calorimetry, and measurements of lipid concentrations. Fasting endogenous glucose production (EGP) increased significantly at one month (12.0 ± 0.7 to 14.9 ± 0.9 μmol/kg/min, P < 0.03), and the increase was sustained at six months of GH treatment (14.0 ± 1.1μ mol/kg/min, NS). This increase in EGP was driven in part by increased glucogenesis (GNG) (3.5 ± 0.9 to 5.2 ± 0.9 and 5.8 ±1.2 μmol/kg/min, n = 4, P < 0.01 and P < 0.01 at one and six months, respectively); small changes in hepatic glycogenolysis also contributed. Sustained increases in lipolysis and progressive decreases in hepatic fractional de novo lipogenesis (DNL) and triglyceride concentrations occurred with GH treatment. These changes were accompanied by an improved lipid profile with a significant increase in HDL cholesterol and significant decreases in total and LDL cholesterol and triglyceride levels, the latter consistent with the decrease in hepatic DNL. During a hyperinsulinemic-euglycemic glucose clamp, EGP and GNG were markedly suppressed compared to the corresponding time points under fasting conditions, albeit less so when measured after one month of GH treatment. Thus, in HIV-infected patients with abnormal fat distribution, pharmacologic doses of GH improved the overall lipid profile, but worsened glucose homeostasis under both fasting and hyperinsulinemic conditions. The combined implications of these positive and negative metabolic effects for cardiovascular disease risk remain unknown.

Sign in / Sign up

Export Citation Format

Share Document